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Abstract
In case of degenerative disease or lesion, bone tissue replacement and regeneration is an important clinical goal. In
particular, nowadays, critical size defects rely on the engineering of scaffolds that are 3D structural supports, allowing
cellular infiltration and subsequent integration with the native tissue. Several ceramic hydroxyapatite (HA) scaffolds with
high porosity and good osteointegration have been developed in the past few decades but they have not solved
completely the problems related to bone defects. In the present study we have developed a novel porous ceramic
composite made of HA that incorporates magnetite at three different ratios: HA/Mgn 95/5, HA/Mgn 90/10 and HA/Mgn 50/
50. The scaffolds, consolidated by sintering at high temperature in a controlled atmosphere, have been analysed in vitro
using human osteoblast-like cells. Results indicate high biocompatibility, similar to a commercially available HA bone graft,
with no negative effects arising from the presence of magnetite or by the use of a static magnetic field. HA/Mgn 90/10 was
shown to enhance cell proliferation at the early stage. Moreover, it has been implanted in vivo in a critical size lesion of the
rabbit condyle and a good level of histocompatibility was observed. Such results identify this scaffold as particularly relevant
for bone tissue regeneration and open new perspectives for the application of a magnetic field in a clinical setting of bone
replacement, either for magnetic scaffold fixation or magnetic drug delivery.
Citation: Panseri S, Cunha C, D’Alessandro T, Sandri M, Russo A, et al. (2012) Magnetic Hydroxyapatite Bone Substitutes to Enhance Tissue Regeneration:
Evaluation In Vitro Using Osteoblast-Like Cells and In Vivo in a Bone Defect. PLoS ONE 7(6): e38710. doi:10.1371/journal.pone.0038710
Editor: Jorge Sans Burns, University Hospital of Modena and Reggio Emilia, Italy
Received January 31, 2012; Accepted May 9, 2012; Published June 7, 2012
Copyright:  2012 Panseri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors strongly acknowledge the financial support from European Union project ‘‘MAGISTER’’ NMP3-LA-2008-214685. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: s.panseri@biomec.ior.it
Introduction
Critical-sized bone defects are generally caused by trauma, bone
diseases, prosthetic implant revision or tumor excision. The
consequent bone tissue loss cannot be repaired by physiological
regenerative processes. In these circumstances, current orthopae-
dic practice for critical-sized bone defects is to use autologous bone
grafts, bone allografts, or synthetic graft materials. However, these
strategies are unable to solve completely the problem, and
motivate the development of novel orthopaedic strategies based
on tissue engineering approaches to facilitate bone regeneration
and repair [1,2,3]. In order to achieve this goal, scaffolds that
mimic the three-dimensional (3D) tissue structure, are the most
promising solutions. They must be biocompatible and osteocon-
ductive with porosity ranging from 300–1000 mm diameter,
necessary in supporting cell migration, proliferation, growth
factor/nutrients diffusion [4,5]. Porous bioceramic scaffolds have
already demonstrated their excellent biocompatibility, bioactivity
and osteoconductivity. In particular, hydroxyapatite (HA) based
scaffolds are of significant interest since hydroxyapatite is the
major inorganic component of natural bone [6]. In spite of this
fact, none of the current HA scaffolds are able to entirely meet the
demands of regenerative medicine strategies for bone repair.
These treatments are unsuccessful especially for the case of large
3D scaffolds that lack rapid vascularisation. The ideal solution will
enhance tissue regeneration and re-vascularisation with a contin-
uous spatially-controlled delivery of cells and/or specific growth
factors such as Vascular Endothelial Growth Factor (VEGF). In
this way a more rapid and well-organized cell scaffold colonization
will occur and it will be possible to control not only the timing but
also the quality of the new tissue formation playing with the
specific growth factors delivery.
Recently, the usage of magnetic nanoparticles (MNPs) for
biological and medical purposes has been increasing and their
biocompatibility is validated by several studies [7,8,9]. MNPs are
unique in their reaction applications (e.g., hyperthermia, contrast
agent for MRI, magnetic drug delivery and cell mechanosensitive
receptor manipulation to induce cell differentiation), whereas only
few authors have proposed approaches for their use in tissue
engineering [10,11,12,13,14]. There are several limitations to the
clinical application of a magnetic field for targeted therapy of a
magnetic drug or for cell delivery. In fact, since the magnetic
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38710gradient decreases with the distance to the target, the main
limitation of magnetic delivery relates to the strength of the
external field that can be applied to obtain the necessary magnetic
gradient to control the residence time of MNPs in the desired area
or which triggers the drug desorption [15,16]. The limitations
inherent to the use of external magnetic fields can be circumvented
by introduction of internal magnets located in the proximity of the
target by minimally invasive surgery or by using a super-
paramagnetic scaffold under the influence of an externally applied
magnetic field. In the latter, the magnetic moment of these
scaffolds affords the potential for their continuous control and
reloading with several tissue growth factors [17,18]. The scaffolds
will act effectively as a fixed ‘‘station’’ that provides long-term
maintenance to the implanted tissue engineering constructs,
providing the unique possibility to adjust the scaffold activity to
the personal needs of the patient, overcoming the present
difficulties of magnetic guiding. With this in mind, we have
developed magnetic fully interconnected porous HA ceramic
scaffold, by a ‘foaming’ technique in which different concentra-
tions of magnetite nanoparticles were added during the synthesis.
This study evaluates first the in vitro biocompatibility of these novel
magnetic scaffolds in the presence or absence of a magnetic field,
and afterwards the in vivo behavior of the most promising scaffold
for clinical application in the repair of a bone defect.
Materials and Methods
Scaffold synthesis and characterization
The commercial HA powder (Finceramica Faenza Spa, Italy)
was calcined at 1000uC for 2 hours in order to decrease the
specific surface area value and prepare stable suspensions with
higher solid loading. The optimized suspensions were prepared by
ball mixing deionized water, 1.5 wt % of dispersant Dolapix CE-
64 (Zschimmer & Schwarz, Lahnstein, Germany) and HA and
Mgn powders having a specific surface area value of 3.93 m
2/g
and 10.41 m
2/g, respectively. The following composite nominal
compositions have been prepared: HA/Mgn weight ratio=100/0,
95/5, 90/10 and 50/50. The HA/Mgn 100/0 scaffold represents
the control group; this HA scaffold is already commercially
available as a biomimetic bone graft (Engipore, Finceramica
Faenza Spa, Italy). The free volume of the closed vessel used,
compared to that occupied by the suspension, was set equal to
40% in volume. After 8 hours at 13 r.p.m, when an homogeneous
slurry was obtained, 1.4 wt % of foaming agent (Dermocin BS,
Fratelli Ricci, Italia) was added. After 12 hours the foamed slurry
was casted in water draining moulds, allowing the setting of the
foamed system and finally dried in air at room temperature for
48 hours. The thermal treatment and in particular the atmosphere
conditions have been investigated so that to maintain high
magnetization value (associated with the starting amount of
magnetite powder) and to reach the highest consolidation extent.
In particular, controlled atmosphere in Ar and of Ar/H2 were
used up to a sintering temperature of 1200uC for 1 h. The
volumetric density (apparent density) r of the foams was
determined from the mass and dimensions of the sintered bodies.
The porosity P was then calculated as P=12r/rth, with rth
corresponding to the theoretical density values of the HA/Mgn
composites, calculated taking into account the theoretical value
3.16 g/cm
3 for HA, 5.2 g/cm
3 for magnetite and hematite and
4.9 g/cm
3 for maghemite. Scanning electron microscopy (SEM;
Stereoscan 360, Leica, Cambridge, UK) equipped with RX
microprobe (EDS: INCA 300, Oxford Instruments, UK) was used
for morphological and compositional evaluations. An optical
microscope (Mic-D Digital Microscope, Olympus, Milano, Italy)
was also used to investigate the pore sizes, window opening (pore
interconnections) and strut thickness, measured with the help of an
image analysis commercial software package (Image Pro-plus
4.5.1. Media Cybernetics, Silver Springs, MD). Magnetic mea-
surements were performed at higher field in a superconducting
quantum interference device (SQUID) magnetometer from
Quantum Design (San Diego, CA, USA), capable of operating




Figure 1. Cell proliferation assay. The Picogreen DNA content assay was performed on cultures of osteoblast-like cells seeded on different HA/
Mgn scaffolds at 7, 14 and 21 days of culture, either in the presence or absence of a magnetic field (MF) (n=5). HA porous scaffold is used as control
group. * p#0.05.
doi:10.1371/journal.pone.0038710.g001
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Saos-2 Human Osteoblast-like cells purchased by Lonza (Italy)
were cultured in Dulbecco Modified Eagle’s Medium (DMEM,
PAA, Austria), containing penicillin/streptomycin (100 U/
100 mg/ml) supplemented with 10% fetal bovine serum and kept
at 37uC in an atmosphere of 5% CO2. Cells were detached from
culture flasks by trypsinization and centrifuged; cell number and
viability were assessed with trypan-blue dye exclusion test.
Scaffolds were 6.00 mm diameter and 4.00 mm high, sterilized
by 25 kGy c-ray radiation prior to use. Scaffolds were placed one
per well in a 24-multiwell plate well and pre-soaked in culture
medium. Each scaffold was seeded by carefully dropping 50 mlo f
cell suspension (5610
4 cells) onto the scaffold upper surface, and
allowing cell attachment for 1 h, before addition into each well of
1 mL of cell culture medium supplemented with 10 mg/ml
ascorbic acid and 5 mM b-glycerophosphate for osteoblast
activation. After a 6 h incubation step, each scaffold was carefully
placed in a new 24 multiwell plate to eliminate any contribution of
remnant cells from the cell suspension that might grow into the
scaffold from its bottom surface. The medium was changed every
2 days. The experiments were conducted either with or without
applying a magnetic field of 320 mT (MagnetoFACTOR-24,
Chemicell, Germany) under the plates for each time point: 7 days,
14 days and 21 days, and osteoblast proliferation and activity in
each scaffold analyzed. All cell handling procedures were
performed in a sterile laminar flow hood. All cell culture
incubation steps were performed at 37uC with 5% CO2.
Cell proliferation assay
Total DNA content was quantified using the PicoGreen dsDNA
(Invitrogen) assay following the manufacturer’s suggested protocol.
Briefly, five seeded scaffolds for each group per time point were
transferred to a new multiwell plate and incubated with 1 ml 16
PBS with 0.1% (v/v) Triton-X for cell lysis. The sample was
centrifuged at 11000 rpm for 1 min. 25 mL of supernatant was
added to 175 mL of PicoGreenH reagent working solution in a 96-
well plate. Fluorescence of the samples was measured with a
microplate reader (Tecan, Research Triangle Park, NC) with
excitation and emission wavelengths of 485 and 535 nm,
respectively. The total number of cells in the sample was
determined by converting the total DNA to cell number using
the conversion factor of 7.7 pg DNA/cell [19]. Five samples were
analysed per time point.
Alkaline Phosphatase assay
Cell Alkaline Phosphatase (AP) activity was quantified using an
enzymatic assay based on the hydrolysis of p-nitrophenyl
phosphate (pNP-PO4)t op-nitrophenol (pNP) [20]. Briefly, samples
were transferred to a new multiwell and incubated with 1 ml 16
PBS with 0.1% (v/v) Triton-X. The sample was centrifuged at
11000 rpm for 1 min. Supernatant was added to pNP-PO4
solution (Sigma-Aldrich) and allowed to react at 37uC. Absorbance
was read at 0, 1, 2 and 3 min at lmax of 405 nm, using a Lambda
35 UV/VIS Spectrometer (PerkinElmer). AP activity was
normalized to total cell number as measured by the Picogreen
assay, at each time point AP activity was expressed as nanomoles
of p-nitrophenol liberated per cell. Five samples were analysed per
each time point.
Live/Dead viability assay
Live/Dead viability assay was performed using a commercial
kit, according to manufacturer’s instructions (BioVision Research
Products, Mountain View, CA, USA). Briefly, the Live/Dead
solution was prepared by adding equal amounts of 1 mM Live-
Dye and 2.5 mg/ml Propidium Iodide to the provided staining
buffer. Samples were washed with 16 PBS for 5 min and
Figure 2. Alkaline phosphatase activity assay. AP activity was measured on different HA/Mgn scaffolds seeded with human osteoblast-like cells
at 7, 14 and 21 days, either in the presence or absence of a magnetic field (MF) (n=5). Results are normalized to control.
doi:10.1371/journal.pone.0038710.g002
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dark. Samples were rinsed three times in PBS, finely cut with a
scalpel in order to examine also the internal surface, and images
were acquired by an inverted Nikon Ti-E fluorescence microscope
(Nikon). Three samples per time point were analysed.
Actin staining
Samples were washed with 16 PBS for 5 min, fixed with 4%
(w/v) paraformaldehyde for 15 min and washed with 16PBS for
5 min. Permeabilization was performed with 16PBS with 0.1%
(v/v) Triton X-100 for 15 min. FITC-conjugated Phalloidin
antibody (Invitrogen) 1:500 in 16 PBS was added for 30 min at
37uC in the dark. Samples were washed with 16PBS for 5 min
and incubated with 300 nM DAPI solution (Invitrogen) for 5 min.
Samples were washed with 16PBS for 5 min and then finely cut
with a scalpel in order to examine also the internal morphology.
Analysis and imaging were performed by an Inverted Nikon Ti-E
fluorescence microscope (Nikon). Three samples per time point
were analysed.
SEM characterization
Cell seeded scaffolds were imaged and characterized using a
SEM Stereoscan 360 Scanning Electron Microscope (Cambridge
Instruments, UK). Samples were washed with 0.1 M sodium
cacodylate buffer pH 7.4 and fixed in 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer pH 7.4 for 2 h at 4uC, washed in
0.1 M sodium cacodylate buffer pH 7.4 and dehydrated in a
graded series of ethanol for 10 min each. Dehydrated samples
were finely cut with a scalpel in order to examine also the internal
morphology, and then sputter-coated with gold using a Polaron
Range sputter coater (DentonVaccum, USA) and mounted on a
copper grid to be examined at SEM. One sample per time point
was analysed.
In vivo pilot experiment and histological analysis
The study was performed in accordance with EC guidelines (EC
Council Directive 86/609, 1986) and the Italian legislation on
animal experimentation (Decreto L. vo 116/92). The research
protocol on animals has been approved by the Ethical Committee
of Rizzoli Orthopaedic Institute and by the responsible public
authorities. Six male rabbits (Oryctolagus cuniculus, Charles River,
Figure 3. Analysis of cell viability. Cell viability was analysed by the Live/Dead assay (n=3). Live-Dye stains for live cells in green, Propidium
Iodide stains for dead cells in red. A) Control at day 7. B) HA/Mgn 95/5 at day 7. C) HA/Mgn 90/10 at day 7. D) HA/Mgn 50/50 at day 7. E) HA/Mgn 95/5
at day 14. F) HA/Mgn 95/5 at day 14. G) HA/Mgn 50/50 at day 14 with applied magnetic field. Scale bars: A–D) 500 mm. E) 250 mm. F, G) 100 mm.
doi:10.1371/journal.pone.0038710.g003
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temperature of 2261uC and relative humidity of 5565% in single
boxes and fed a standard diet (Mucedola, Milano, Italy) with
filtered tap water ad libitum. After quarantine of at least 10 days,
the animals were fasted for 24 hours before surgery. The animals
were subjected to surgery to implant the tested scaffolds at the
distal femoral epiphysis under general anaesthesia and in aseptic
conditions. After having shaved and disinfected the posterior legs,
the animals underwent a lateral longitudinal incision of lateral
femoral condyle. Femoral lateral condyle trabecular bone was
cross-sectionally drilled at low speed and a profuse irrigation with
cold sterile 0.9% NaCl solution was maintained throughout the
process to prevent the risk of bone necrosis. A critical bone defect
of 6.00 mm in diameter and 8.00 mm in depth was made in each
lateral femoral condyle. All six animals were subjected to the
implantation of one HA/Mgn 90/10 scaffold and one HA scaffold
was implanted in the contralateral condyle as a control group.
Scaffolds were 6.00 mm diameter and 8.00 mm high, sterilized by
25 kGy c-ray radiation. Finally, the skin was sutured. General
anaesthesia was induced by an intramuscular injection of 44 mg/
kg ketamine (Imalgene 1000, Merial Italia S.p.A, Milan, Italy) and
3 mg/kg xylazine (Rompun, Bayer SpA, Milano, Italy) under
assisted ventilation with O2/N2O (1/0.4 l/min) mixture and 2.5%
isofluorane (Forane, Abbot SpA, Latina, Italy).
Post-operatively, antibiotics and analgesics were administered:
0.6 ml/kg flumequil (Flumexil, (FATRO SpA, Bologna, Italy) and
0.1 ml/kg/day metamizole sodium (Farmolisina, Ceva Vetem
SpA, Monza-Brianza, Italy).
At 4 weeks after surgery, the animals were pharmacologically
euthanized with intravenous administration of Tanax (Hoechst,
Frankfurt am Main, Germany), under general anaesthesia. The
operated bone segments were excised and stripped of soft tissue
and the presence of haematomas, oedema, and inflammatory
tissue reactions were macroscopically evaluated. The bone
segments were fixed in 4% buffered paraformaldehyde for
24 hours, dehydrated in a graded series of alcohol and finally
embedded in a methyl methacrylate resin (Merck Schuchardt
OHG, Hohenbrunn, Germany). Using a saw microtome (Leica
SP1600, Leica Microsystems Srl, Italy), three consecutive central
sections to the major axis of the implant for each bone segment
were cut (60620 mm) and polished (Struers Dap-7, Struers Tech
A/S, Rodovre/Copenaghen, Denmark). Then, thinned sections
(30610 mm) were stained with Toluidine Blue, Acid Fucsin and
Fast Green.
Statistical analysis
For cell proliferation and AP activity, results were expressed as
MEAN6SEM plotted on graph (n=5). Statistical analysis was
performed using two-way ANOVA, followed by Bonferroni’s post-
hoc test, for the analysis of magnetic field effect, time effect and
magnetic field versus time effect. Analysis of differences between
groups, for each time point, was performed by one-way ANOVA,
followed by Tukey’s post-hoc test. All statistical analysis made use
of the GraphPad Prism software (version 5.0), with a=0.05.
Results
No undesired secondary phases were detected by XRD in the
sintered magnetic composites, beside hydroxyapatite and magne-
tite: the starting nominal composition was maintained up to
10 wt% of magnetite. For higher magnetite content abouot
20 wt% of hematite was detected as secondary phase. The
sintered composites showed a total porosity ranging between 73 to
78%. As observed by SEM, the microstructure of the sintered
samples is characterized by large pores in the range 300–800 mm
uniformly distributed throughout the sample with numerous
interconnections (average dimension=100–150 mm) between the
individual macropores. Moreover SEM/EDS investigation
showed that the magnetic phase is uniformly distributed and
merged in the calcium phosphate matrix. At high magnetic field
(7 N A
21 m
21) magnetization showed values of 34 and 53 emu/g
for the samples containing 5 wt% and 10 wt% of magnetite
respectively; while dropped at 37 emu/g in case of the composite
containing 50 wt% of magnetite due to the presence of hematite as
secondary phase.
Here, we analyzed effects of the addition of magnetite for bone
tissue regeneration in vitro, using Human osteoblast-like cells and in
vivo on a critical lesion of the rabbit femoral condyle as a pilot
study.
The in vitro investigation was performed on cell-seeded scaffolds,
where cells were seeded onto the scaffold surface. All the
experiments were conducted with or without applying a 320 mT
magnetic field and the analysis of osteoblast proliferation and
activity in each scaffold has been performed at 7, 14 and 21 days
post-seeding.
We have observed an overall increase in cell proliferation from
day 7 to day 21 for all groups. Moreover, we have found a
statistical significant increase in cells seeded on the HA/Mgn 90/
10 after 7 days, both with or without a magnetic field (Fig. 1). At
day 14, the group HA/Mgn 90/10 continued to have higher cell
proliferation respect to the other groups, with this trend
maintained until the end of the experiment (Fig. 1).
Alkaline phosphatase activity, an osteogenic marker, was
analysed and results normalized with the control. No statistically
significant differences were found between experimental groups,
and the applied magnetic field did not affect the cellular alkaline
phosphatase activity (Fig. 2).
The Live/Dead assay showed a very high ratio of viable cells at
each experimental time point, with a range between 73.964.3%
and 92.863.0% and no differences between groups. No significant
effect of magnetic field application was observed. After 7 days of
culture, cells cover nearly the entire upper scaffold surface
Figure 4. Analysis of cell morphology. Cell morphology was
analysed by actin staining (n=3). Actin is shown in green, DAPI in blue.
A) Control at day 14. B) HA/Mgn 90/10 at day 14. C) Control at day 21
with applied magnetic field. D) HA/Mgn 90/10 at day 21 with applied
magnetic field. Scale bars: A, B) 250 mm. C, D) 100 mm.
doi:10.1371/journal.pone.0038710.g004
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infiltrated the scaffolds as shown in Fig. 3E. The very small ratio of
dead cells found on magnetic materials was very similar to that
found in the HA group for all time points (Fig. 3A–E). We
analyzed also the inner surface after cutting the samples. After 14
days, cells had infiltrated into the scaffold and a high number of
live cells were seen in all groups (Fig. 3F, G).
Analysis of phalloidin staining on day 7, 14 and 21 after seeding
did not reveal differences in cell morphology between groups, in
the presence or absence of a magnetic field. Attached cells
exhibited their characteristic intricate morphology both on the
external and inner surface (Fig. 4 A–D).
Detailed cell morphology was analysed by scanning electron
microscopy. After 7 days, cells almost covered the external surface
of the entire scaffold, and infiltrated into the pores (Fig. 5A–D).
Significant integration of cells to the scaffold was also confirmed
by SEM images. In fact after 14 days cells were firmly attached the
to scaffold surface and the scaffold external surface was completely
embedded by a cell layer and no differences were found between
groups (Fig. 5 E, F). The inner section of each scaffold showed that
after 7 days cells had already entered the pores and attached to the
inner surface, as shown by the section reconstruction in Fig. 5G.
Cells seeded onto the upper surface after 7 days migrated through
the interconnected porous structure and cells were seen well
attached to the lower level of the scaffold (Fig. 5G).
Looking at the details, cells not only grew inside the pores, but
they also nicely bridged the porous structure forming a cell
network (Fig. 5 H–K).
Overall, in vitro results showed that there were no differences in
cell viability and cell morphology between groups, but the
quantification of DNA demonstrated that the HA/Mgn 90/10
significantly increase the cell proliferation, in particular in the first
7 days. For this reason, we selected this scaffold for a pilot
experiment in vivo.
At 4 weeks post-implantation, macroscopic evaluation showed
the HA porous implants to be in the proper position and there was
no evidence of haematoma, oedema, infection or tissue necrosis in
either bone and peri-implant soft tissue associated with control or
magnetic implants. Bone tissue was well visible around and inside
the scaffold in both groups (Fig. 6A, C). Due to the interconnected
porous structure, bone regenerated into the magnetic scaffold and
after only 4 weeks some pores were completely full of new bone
Figure 5. SEM characterization of cell seeded scaffolds. Detailed analysis of cell morphology was assessed by scanning electron microscopy.
A) Control at day 7. B) HA/Mgn 95/5 at day 7. C) HA/Mgn 90/10 at day 7. D) HA/Mgn 50/50 at day 7. E) Control at day 14 with applied magnetic field.
F) HA/Mgn 90/10 at day 14 with applied magnetic field. G) HA/Mgn 95/5 at day 7, vertical overlapping profile of 3 consecutive images. H) Control at
day 7. I, J) HA/Mgn 90/10 at day 7. K) HA/Mgn 95/5 at day 7. Scale bars: A–D) 150 mm, E, F) 10 mm, G) 500 mm, H, I) 50 mm, J) 50 mm, K) 20 mm.
doi:10.1371/journal.pone.0038710.g005
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comparable to the control group (Fig. 6B, D).
Discussion
The spatial and physical properties as well as biochemistry of
biomaterials strongly influence cell growth into a scaffold. It is well
known that a highly porous scaffold is desirable in tissue
engineering, since it can support the necessary nutrient transport
for tissue regeneration [21,22]. Porosity also plays an important
role in cell migration whereas pore interconnectivity increases the
overall surface area for cell attachment and facilitates cell ingrowth
into the scaffolds. Notwithstanding the fact that many scaffolds
with these features were developed in the last few decades to treat
critical bone defects, none have been adopted for routine
treatment of bone defects in the clinic.
The magnetic scaffolds presented in this study were well
chemically characterized and exhibited good biocompatibility, as
assessed previously (manuscript in preparation). Here, 3D cell
cultures were investigated in order to better understand which
scaffold would promote more rapid cell scaffold colonization and
subsequent tissue regeneration in in vivo applications. The in vitro
results showed good cell distribution and cell morphology in the
range of magnetic HA scaffolds studied, comparable to the
magnetite-free control scaffold already used clinically for bone
repair. The application of magnetic field did not adversely affect
cell morphology or alkaline phosphatase activity, indicating that
higher magnetization can be used for prosthesis fixation purposes
or for guidance without impairing bone tissue regeneration.
With respect to osteoblast performance on each scaffold, a
significant difference was found in cell proliferation between the
HA/Mgn 90/10 scaffold and the remaining groups, although AP
activity did not significantly increase, reflecting an osteoblast
commitment towards proliferation. Cell number was considerably
higher in particular in the first week after seeding, therefore the
HA/Mgn 90/10 scaffold has the potential to strongly enhance in
vivo tissue regeneration at an early stage.
There is debate regarding the use of magnetite in medical
applications. There are studies that demonstrate the toxic effect of
magnetite on cell culture, but at the same time there are several
works that show the opposite result. In particular, if we focus on
the magnetite use for scaffold in musculoskeletal application, there
are numerous studies with good results both with stem cells or cell
lines which are in accordance with our results [23,24,25,26].
For the above-mentioned reasons, the HA/Mgn 90/10
construct was evaluated in a critical-sized defect of the rabbit
femoral condyle as a pilot experiment. After 4 weeks, the HA/
Mgn 90/10 construct showed mineralized tissue regeneration into
its structure in a similar manner as the control non-magnetized
HA construct.
The optimal tissue regeneration process, in addition to scaffold
properties, depends on a complex cascade of biological events
controlled by an interplay of cytokines and growth factors. These
provide local signals at sites of injury, which regulate the
mechanisms and pathways that govern tissue regeneration
[27,28]. For instance, the creation of a vascular network assuring
diffusion of nutrients and removal of metabolites over long
distances are critical for guiding osteogenesis. As such, insufficient
activation of signalling molecules and, in particular, the generation
of a poor vascular network often impedes new bone formation
[29,30].
The encouraging results obtained in vivo with the HA/Mgn 90/
10 scaffold open future prospects in bone tissue engineering and
also for the use of an applied magnetic field for various clinical
applications. In fact, under an external magnetic field, this scaffold
can be activated and function like a magnet, attracting
functionalized magnetic nanoparticles injected close to the
scaffold. Using this approach, strategies for drug delivery using
Figure 6. Histological evaluation of the in vivo implanted scaffolds. Toluidine Blue, Acid Fucsin and Fast Green staining shows similar
histocompatibility for both scaffolds 4 weeks after implantation (n=6). A, B) Control, C, D) HA/Mgn 90/10. Scale bars: A, C) 1 mm, B, D) 500 mm.
doi:10.1371/journal.pone.0038710.g006
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particle loss [15,16]. Thus, there is potential to enhance tissue
regeneration via delivery of several growth factors that can be
accurately released close to or into the scaffold. Magnetic scaffolds
could provide a novel and simple solution to the general problem
of orthopaedic device fixation [31,32]. We envision that efficient
scaffold fixation via magnetic forces could be achieved by
magnetization of the scaffold at a level sufficient to activate an
attractive force towards selected anchoring magnetic objects.
Improved outcomes associated with the use of engineered
orthopaedic tissues will depend upon an optimized scaffold design
that provides 3D structural support, allows initial cellular transport
and promotes subsequent integration with native tissue. These
aspects are likely to be enhanced by modifications that improve
the ability of scaffolds to deliver growth factors at therapeutic levels
during tissue regeneration. The development and use of magnetic
scaffolds, such as those described in this study, in conjunction with
magnetic drug delivery constitute a very innovative and promising
technology to treat not only musculoskeletal defects but several
pathologies in the area of regenerative medicine.
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